Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations by Yueming He, Yitao Wu, Rongqi He, Meng Xu, Heshan Chen, Yiran Meng, Liuqing Zheng, Li Wang

Get full text

Biological and prognostic insights into the prostaglandin D2 signaling axis in lung adenocarcinoma by Qiang Liu, Huiguo Chen, Dongfang Tang, Huibiao Zhang, Shaogeng Chen, Yiran Meng, Boying Zheng, Fei Liu, Jing Zhou, Wen Zhang

Get full text

Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers by Chenglin Yang, Jiahao Qu, Jingting Wu, Songhua Cai, Wenyi Liu, Youjun Deng, Yiran Meng, Liuqing Zheng, Lishen Zhang, Li Wang, Xiaotong Guo

Get full text

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer by Zhengyu Zha, Chunxiao Liu, Meisi Yan, Cong Chen, Cheng Yu, Yaohui Chen, Chenhao Zhou, Lu Li, Yi-Chuan Li, Hiro Yamaguchi, Leiguang Ye, Tong Liu, Ying-Nai Wang, Heng-Huan Lee, Wen-Hao Yang, Li-Chuan Chan, Baozhen Ke, Jennifer L. Hsu, Lieming Ding, Dong Ji, Peng Pan, Yiran Meng, Yue Pu, Lunxu Liu, Mien-Chie Hung

Get full text